- Home
- STGW vs ERAS Comparison
STGW vs ERAS Comparison
Compare STGW & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- ERAS
- Stock Information
- Founded
- STGW 1980
- ERAS 2018
- Country
- STGW United States
- ERAS United States
- Employees
- STGW N/A
- ERAS N/A
- Industry
- STGW
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- ERAS Health Care
- Exchange
- STGW Nasdaq
- ERAS Nasdaq
- Market Cap
- STGW 814.3M
- ERAS 723.8M
- IPO Year
- STGW N/A
- ERAS 2021
- Fundamental
- Price
- STGW $6.82
- ERAS $2.54
- Analyst Decision
- STGW Strong Buy
- ERAS Strong Buy
- Analyst Count
- STGW 5
- ERAS 5
- Target Price
- STGW $8.50
- ERAS $5.90
- AVG Volume (30 Days)
- STGW 434.5K
- ERAS 1.5M
- Earning Date
- STGW 11-07-2024
- ERAS 11-12-2024
- Dividend Yield
- STGW N/A
- ERAS N/A
- EPS Growth
- STGW N/A
- ERAS N/A
- EPS
- STGW 0.00
- ERAS N/A
- Revenue
- STGW $2,707,403,000.00
- ERAS N/A
- Revenue This Year
- STGW $13.05
- ERAS N/A
- Revenue Next Year
- STGW N/A
- ERAS N/A
- P/E Ratio
- STGW $5,790.36
- ERAS N/A
- Revenue Growth
- STGW 4.92
- ERAS N/A
- 52 Week Low
- STGW $4.88
- ERAS $1.64
- 52 Week High
- STGW $8.18
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- STGW 32.57
- ERAS 41.70
- Support Level
- STGW $7.32
- ERAS $2.51
- Resistance Level
- STGW $7.40
- ERAS $2.68
- Average True Range (ATR)
- STGW 0.27
- ERAS 0.19
- MACD
- STGW -0.13
- ERAS -0.05
- Stochastic Oscillator
- STGW 6.52
- ERAS 17.39
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; Communications Network and other. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.